Drug Database · Clinicians

Amlodipine + Atorvastatin

Brands (36) Norvasc Protect, Amlodine HD, Amlog Plus…Show all

US brand (reference label): Caduet; not a Philippine-registered brand.

Calcium channel Blocker/HMG-CoA reductase inhibitor (lipid modifying agent); HMG coa reductase Inhibitor/Calcium channel blocker; and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug65 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 164394b3-d7ba-4bbf-b64b-e2dd15735ea8, version date September 30, 2026 (Caduet · Viatris Specialty LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate.
  • .
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. CADUET is a combination of amlodipine besylate, a calcium channel blocker, and atorvastatin calcium, a HMG-CoA-reductase inhibitor (statin), indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate (1).

Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Amlodipine is indicated for the treatment of Coronary Artery Disease (1). Atorvastatin is indicated (1):

  • To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD.
  • As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
  • As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia.
  • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Amlodipine Hypertension Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine may be used alone or in combination with other antihypertensive agents. Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction < 40%, amlodipine is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. Atorvastatin Atorvastatin is indicated:
  • To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD
  • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
  • As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).
  • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia o Hypertriglyceridemia

Contraindications

4 CONTRAINDICATIONS • Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)]. • Hypersensitivity to amlodipine, atorvastatin or any excipients in ‎CADUET. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported [see Adverse Reactions (6.2)]. • Acute liver failure or decompensated cirrhosis (4). • Hypersensitivity to amlodipine, atorvastatin or any excipient in CADUET (4).

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

2 DOSAGE AND ADMINISTRATION Usual starting dose (mg daily) Maximum dose (mg daily) Amlodipine 5 Start small adults or children, fragile, or elderly patients, or patients with hepatic insufficiency on 2.5 mg once daily (2). 10 Atorvastatin 10–20 Start patients requiring large LDL-C reduction (> 45%) at 40 mg once daily (2). 80 CADUET Dosage of CADUET must be individualized on the basis of both effectiveness and tolerance for each individual component in the treatment of hypertension/angina and hyperlipidemia. Select doses of amlodipine and atorvastatin independently.

CADUET may be substituted for its individually titrated components. Patients may be given the equivalent dose of CADUET or a dose of CADUET with increased amounts of amlodipine, atorvastatin, or both for additional antianginal effects, blood pressure lowering, or lipid-lowering effect. CADUET may be used to provide additional therapy for patients already on one of its components.

CADUET may be used to initiate treatment in patients with hyperlipidemia and either hypertension or angina. Important Dosage Information Take CADUET orally once daily at any time of the day, with or without food. Amlodipine The usual initial antihypertensive oral dosage of amlodipine is 5 mg once daily, and the maximum dose is 10 mg once daily.

Pediatric (age > 6 years), small adult, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding amlodipine to other antihypertensive therapy. Adjust dosage according to blood pressure goals. In general, wait 7 to 14 days between titration steps.

Titration may proceed more rapidly, however, if clinically warranted, provided the patient is assessed frequently. Angina The recommended dosage of amlodipine for chronic stable or vasospastic angina is 5–10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Most patients will require 10 mg for adequate effect.

Coronary Artery Disease The recommended dosage range of amlodipine for patients with CAD is 5–10 mg once daily. In clinical studies, the majority of patients required 10 mg [see Clinical Studies (14.4)]. Pediatrics The effective antihypertensive oral dose of amlodipine in pediatric patients ages 6–17 years is 2.5 mg to 5 mg once daily.

Doses in excess of 5 mg daily have not been studied in pediatric patients [see Clinical Pharmacology (12.3) and Clinical Studies (14.1)]. Atorvastatin Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin, and adjust the ‎dosage if ‎‎necessary.‎ ‎ Recommended Dosage in Adult Patients The recommended starting dosage of atorvastatin is 10 mg to 20 mg once daily.

The dosage range is 10 mg to 80 mg once daily. Patients who require reduction in LDL-C greater than 45% may be started at 40 mg once daily. Recommended Dosage in Pediatric Patients 10 Years of Age and Older with H e FH The recommended starting dosage of atorvastatin is 10 mg once daily. The dosage range is 10 mg to 20 mg once daily.

Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HoFH The recommended starting dosage of atorvastatin is 10 mg to 20 mg once daily. The dosage range is 10 mg to 80 mg once daily. Dosage Modifications Due to Drug Interactions Concomitant use of atorvastatin with the following drugs requires dosage modification of atorvastatin [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].

Anti-Viral Medications

  • In patients taking saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir or letermovir, do not exceed atorvastatin 20 mg once daily.
  • In patients taking nelfinavir, do not exceed atorvastatin 40 mg once daily. Select Azole Antifungals or Macrolide Antibiotics
  • In patients taking clarithromycin or itraconazole, do not exceed atorvastatin 20 mg once daily. For additional recommendations regarding concomitant use of atorvastatin with other anti-viral medications, azole antifungals or macrolide antibiotics, [see Drug Interactions (7.1)].

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations, pharmacokinetics)

8.6 Renal Impairment Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. Renal impairment does not affect the plasma concentrations of atorvastatin, therefore there is no dosage adjustment in patients with renal impairment [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

Renal Impairment Amlodipine: The pharmacokinetics of amlodipine are not significantly influenced by renal impairment.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment In patients with chronic alcoholic liver disease, plasma concentrations of atorvastatin are markedly increased. C max and AUC are each 4-fold greater in patients with Childs-Pugh A disease. C max and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease. CADUET is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of CADUET have not been established in pediatric populations. Amlodipine Amlodipine (2.5 to 5 mg daily) is effective in lowering blood pressure in patients 6 to 17 years [see Clinical Studies (14.1)]. The effect of amlodipine on blood pressure in patients less than 6 years of age is not known.

Atorvastatin The safety and effectiveness of atorvastatin as an adjunct to diet to reduce LDL-C have been established in pediatric patients 10 years of age and older with HeFH. Use of atorvastatin for this indication is based on a double-blind, placebo-controlled clinical trial in 187 pediatric patients 10 years of age and older with HeFH.

In this limited controlled trial, there was no significant effect on growth or sexual maturation in the males or females, or on menstrual cycle length in females. The safety and effectiveness of atorvastatin as an adjunct to other LDL-C-lowering therapies to reduce LDL-C have been established in pediatric patients 10 years of age and older with HoFH.

Use of CADUET for this indication is based on a trial without a concurrent control group in 8 pediatric patients 10 years of age and older with HoFH [see Clinical Studies (14)]. The safety and effectiveness of atorvastatin have not been established in pediatric patients younger than 10 years of age with HeFH or HoFH, or in pediatric patients with other types of hyperlipidemia (other than HeFH or HoFH).

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Safety and effectiveness of CADUET have not been established in geriatric populations. Amlodipine Clinical studies of amlodipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40–60%, and a lower initial dose may be required [see Dosage and Administration (2)].

Atorvastatin Of the total number of atorvastatin-treated patients in clinical trials, 15813 (40%) were ≥ 65 years old and 2800 (7%) were ≥ 75 years old. No overall differences in safety or effectiveness were observed between these patients and younger patients. Advanced age (≥ 65 years) is a risk factor for atorvastatin -associated myopathy and rhabdomyolysis.

Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving CADUET for the increased risk of myopathy [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

Dosage forms

Philippines

  • Film-coated tablet: 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/5 mg, 10 mg/80 mg, 20 mg/10 mg, 20 mg/5 mg, 40 mg/10 mg, …
  • Tablet: 5 mg/10 mg, 5 mg/20 mg, 10 mg/10 mg, 10 mg/20 mg

Registered products in the Philippines

65 products registered with the Food and Drug Administration (FDA) Philippines list Amlodipine + Atorvastatin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products65
Philippine FDA-registered products for Amlodipine + Atorvastatin
Package insert
A2 PvastAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg /20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-18280-01
Jun 4, 2031
Amlat 10/5Atorvastatin (as calcium trihydrate) + Amlodipine (as besilate)
10 mg/5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 20's
RxVAT-exempt
Amson Vaccine & Pharma (Pvt.) Ltd.Pakistan
Sahar International Trading, Inc.
DRP-8038
Jul 1, 2029
Amlat 20/10Atorvastatin (as calcium trihydrate) + Amlodipine (as besilate)
20 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 20's
RxVAT-exempt
Amson Vaccines & Pharma (Pvt.) Ltd.Pakistan
Sahar International Trading, Inc.
DRP-8036
Jul 1, 2029
Amlat 20/5Atorvastatin (as calcium trihydrate) + Amlodipine (as besilate)
20 mg/5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's)
RxVAT-exempt
Amson Vaccines & Pharma (Pvt.) Ltd.Pakistan
Sahar International Trading, Inc.
DRP-8037
Jul 1, 2029
Amlitor 5Atorvastatin (as calcium) + Amlodipine (as besilate)
10 mg / 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
JWK Enterprises, Inc.Importer: Ambica International Corporation
DRP-2511-07
Oct 7, 2028
Amlitor ForteAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg TabletAlu-Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
JWK Enterprises, Inc.Importer: Ambica International Corporation
DRP-2304-01
Jul 7, 2028
Amlodine HDAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-10216
Jul 8, 2031
Amlodine HDAmlodipine (as besilate) + Atorvastatin (as calcium)
5 mg/20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-10218
Jul 8, 2031
Amlodine HDAmlodipine (as besilate) + Atorvastatin (as calcium)
5 mg/40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DR-XY39599
Jun 14, 2031
Amlog PlusAtorvastatin (as calcium) + Amlodipine (as besilate)
10mg/5mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-13153
Dec 12, 2027
Amlog PlusAtorvastatin (as calcium) + Amlodipine (as besilate)
20 mg/10 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-13152
Dec 12, 2027
Amlog PlusAtorvastatin (as calcium) + Amlodipine (as besilate)
20 mg/5 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-15423
Sep 20, 2029
AmlotinAmlodipine (as besylate) + Atorvastatin (as calcium)
10 mg/ 10 mg Film-Coated TabletAlu/PVC Blister x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd.
DRP-15179
May 21, 2029
AmlotinAmlodipine (as besylate) + Atorvastatin (as calcium)
5 mg/ 20 mg Film-Coated TabletAlu/PVC Blister x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private Limited.India
I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd.
DRP-15178
May 21, 2029
AmlotinAmlodipine (as besylate) + Atorvastatin (as calcium)
5 mg/10 mg Film-Coated TabletAlu/PVC Blister x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd.
DRP-15177
May 21, 2029
AmtivineAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/ 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-18280-02
Jun 4, 2031
AmtivineAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-18279-02
Jun 4, 2031
AmtorphilAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc.Importer: AMB HK Enterprises Inc
DRP-17720
Mar 3, 2032
Amtorphil: Amlodipine (as besilate) + Atorvastatin (as calcium)
5 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc.
DRP-17718
Mar 3, 2032
AmtorphilAmlodipine (as besilate) + Atorvastatin (as calcium)
5 mg/20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc.
DRP-17719
Mar 3, 2032
AtorlopinAtorvastatin (as calcium) + Amlodipine (as besilate)
10 mg / 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Camber Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-2511-08
Oct 7, 2028
AtorpineAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-2304-06
Jul 7, 2028
ATV PlusAmlodipine (as Besilate) + Atorvastatin (as Calcium)
5 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack X 10's (Box of 10's and 30's)
RxVAT-exempt
Delta Pharma Ltd.Bangladesh
Biomed Pharma Inc.
DR-XY39604
Jun 13, 2031
CordistatAtorvastatin (as calcium) + Amlodipine (as besilate)
10 mg/ 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-2511-02
Oct 7, 2028
CordistatAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-2304-02
Jul 7, 2028
CortiVasAmlodipine (as besilate) + Atorvastatin (as calcium)
5 mg / 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Shanghai Pharma (Philippines) Inc.Importer: Ambica International Corporation
DRP-6802-01
Aug 19, 2030
CorvastelAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/ 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-18280-03
Jun 4, 2031
DualpressAmlodipine (as besilate) + Atorvastatin (as calcium)
5 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Standard Chem. & Pharm. Co., Ltd. (Plant II)Taiwan
Standard Chem & Pharm. Philippines, Inc.
DRP-11153
Feb 8, 2027
IlorstiveAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/ 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-18280-04
Jun 4, 2031
Lipend A-50Atorvastatin (as calcium) + Amlodipine (as besilate)
40 mg/10 mg Film-Coated TabletAlu/Alu Blister Pak x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International CorporationTrader: Endurance Healthcare Ltd.
DRP-5004
Dec 10, 2028
Lipend A-90Amlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Trader: Endurance Healthcare Ltd.
DRP-6298
Aug 12, 2030
Lipend A-ForteAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Trader: Endurance Healthcare Ltd.
DRP-6272
Aug 7, 2030
Lipimize-A 20Amlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 50’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-6673
May 2, 2030
LipituneAmlodipine (as besylate) + Atorvastatin (as calcium)
10 mg/ 10 mg Film-Coated TabletAlu/PVC Blister x l0's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Vitalife Pharma & Medical Supply Inc.Importer: I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd.
DRP-15179-02
May 21, 2029
LipituneAmlodipine (as besylate) + Atorvastatin (as calcium)
5 mg/ 10 mg Film-Coated TabletAlu/PVC Blister x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Vitalife Pharma & Medical Supply Inc.Importer: I.E. Medica, Inc.
DRP-15177-02
May 21, 2029
LoartinAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-2304-04
Jul 7, 2028
LodivasAtorvastatin Calcium + Amlodipine (As Besilate)
10 mg/5 mg Film Coated TabletAlu/Alu Blister Pack X 10's (Box of 30's)
RxVAT-exempt
Mediwin PharmaceuticalsIndia
Euroasia Pharmaceuticals, IncTrader: Tunic Healthcare
DRP-10112
Sep 21, 2030
LotorpineAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/ 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-18280-06
Jun 4, 2031
LotorpineAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-18279-03
Jun 4, 2031
MiravastAtorvastatin (as calcium) + Amlodipine (as besilate)
10 mg/ 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Miraculin Pharma Inc.Importer: Ambica International Corporation
DRP-2511-03
Oct 7, 2028
MiravastAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg TabletAlu/Alu Blister Pack x 10's Box of 100's
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Miraculin Pharma Inc.Importer: Ambica International Corporation
DRP-2304-03
Jul 7, 2028
NoneAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/ 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of l00's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
I.E. Medica, Inc.
DRP-13383
Feb 7, 2037
NoneAtorvastatin (as calcium) + Amlodipine (as besilate)
10 mg/ 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation
DRP-2511-04
Oct 7, 2028
NoneAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-2304-05
Jul 7, 2028
NoneAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation
DRP-2304-07
Jul 7, 2028
NoneAtorvastatin (as calcium) + Amlodipine (as besilate)
10 mg/5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-2511-05
Oct 7, 2028
NoneAmlodipine (as besilate) + Atorvastatin (as calcium)
5 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Aisec Farma CorporationImporter: Ambica International CorporationTrader: Endurance Healthcare Ltd.
DRP-6273
Aug 7, 2030
NordinAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Medchoice Pharma, Inc.Importer: Ambica International Corporation
DRP-2304-08
Jul 7, 2028
Norvasc ProtectAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg / 20 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Viatris, Inc.
DRP-16146
Sep 30, 2029
Norvasc ProtectAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/ 10 mg TabletAlu-Alu Blister Pack x l0's Box of 30's
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Viatris, Inc.
DRP-3146
Sep 30, 2029
Norvasc ProtectAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/20 mg TabletAlu-Alu Blister Pack x 10's Box of 30's
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Viatris, Inc.
DR-XY30122
Sep 30, 2029
Norvasc ProtectAmlodipine (as Besilate) + Atorvastatin (as Calcium)
5 mg /20 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Viatris, Inc.
DRP-16147
Sep 30, 2029
Norvasc ProtectAmlodipine (as besilate) + Atorvastatin (as calcium)
5 mg/ 10 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Viatris, Inc.
DRP-2791
Sep 30, 2029
Norvasc ProtectAmlodipine (as Besilate) + Atorvastatin (as Calcium)
5 mg/20 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Viatris, Inc.
DR-XY30121
Sep 30, 2029
Stalip A-50Atorvastatin (as calcium) + Amlodipine (as besilate)
40 mg / 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.
DRP-4963
Nov 27, 2028
Stalip A-90Atorvastatin (as calcium) + Amlodipine (as besilate)
80 mg / 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.
DRP-4907
Nov 13, 2028
Stalip A-ForteAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg TabletAlu/Alu Blister Pack x 10's Box of 30's and 100's
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-2304
Jul 7, 2028
Stalip-AAtorvastatin (as calcium) + Amlodipine (as besilate)
10 mg / 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Bio-Strata Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-2511
Oct 7, 2028
TukonAmlodipine (as besylate) + Atorvastatin (as calcium)
10 mg/ 10 mg Film-Coated TabletAlu/PVC Blister x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Corbridge Group Phils., Inc.Importer: I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd.
DRP-15179-01
May 21, 2029
TukonAmlodipine (as besylate) + Atorvastatin (as calcium)
5 mg / 10 mg Film-Coated TabletAlu / PVC Blister x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Corbridge Group Phils., Inc.Importer: I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd.
DRP-15177-01
May 21, 2029
TukonAmlodipine (as besylate) + Atorvastatin (as calcium)
5 mg/ 20 mg Film-Coated TabletAlu/PVC Blister x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Corbridge Group Phils., Inc.Importer: I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd.
DRP-15178-01
May 21, 2029
UnbrandedAmlodipine (as besilate) + Atorvastatin
5 mg/ 10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd.
DRP-15486
Jul 30, 2031
UnbrandedAmlodipine (as besilate) + Atorvastatin
5 mg/20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd.
DRP-15487
Jul 30, 2031
ValostineAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-18279-01
Jun 4, 2031
ValostineAmlodipine (as besilate) + Atorvastatin (as calcium)
10 mg/20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-18280-05
Jun 4, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS CADUET tablets are formulated for oral administration in the following strength combinations of amlodipine / atorvastatin: 5 mg/10 mg tablets: White, oval, film-coated tablets debossed, blank on one side and with product code on the other side: “CDT” and “051”. 5 mg/20 mg tablets: White, oval, film-coated tablets debossed, blank on one side and with product code on the other side: “CDT” and “052”. 5 mg/40 mg tablets: White, oval, film-coated tablets debossed, blank on one side and with product code on the other side: “CDT” and “054”. 5 mg/80 mg tablets: White, oval, film-coated tablets debossed, blank on one side and with product code on the other side: “CDT” and “058”. 10 mg/10 mg tablets: Blue, oval, film-coated tablets debossed, blank on one side and with product code on the other side: “CDT” and “101”. 10 mg/20 mg tablets: Blue, oval, film-coated tablets debossed, blank on one side and with product code on the other side: “CDT” and “102”. 10 mg/40 mg tablets: Blue, oval, film-coated tablets debossed, blank on one side and with product code on the other side: “CDT” and “104”. 10 mg/80 mg tablets: Blue, oval, film-coated tablets debossed, blank on one side and with product code on the other side: “CDT” and “108”. Tablets contain amlodipine besylate equivalent to amlodipine 5 or 10 mg and atorvastatin calcium equivalent to atorvastatin 10, 20, 40, or 80 mg (3).

Warnings/Precautions

Warnings and precautions (US label) US FDA label

  • Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher CADUET dosage. Discontinue CADUET if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue CADUET in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing CADUET dosage. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever (2, 5.1, 7.3, 8.5, 8.6).
  • Immune-Mediated Necrotizing Myopathy (IMNM): Rare reports of IMNM, an autoimmune myopathy, have been reported with statin use. Discontinue CADUET if IMNM is suspected (5.2).
  • Hepatic Dysfunction: Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzymes before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue CADUET (5.3).
  • Angina or myocardial infarction may occur with initiation or dose increase (5.4).
  • Symptomatic hypotension is possible, …
5.1 Myopathy and Rhabdomyolysis

5.1 Myopathy and Rhabdomyolysis CADUET may cause myopathy (muscle pain, tenderness, or weakness associated with elevated creatine kinase [CK]) and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins, including CADUET.

Risk Factors for Myopathy Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher CADUET dosage [see Drug Interactions (7.3) and Use in Specific Populations (8.5, 8.6)]. Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis CADUET exposure may be increased by drug interactions due to inhibition of cytochrome P450 enzyme 3A4 (CYP3A4) and/or transporters (e.g., breast cancer resistant protein [BCRP], organic anion-transporting polypeptide [OATP1B1/OATP1B3] and P-glycoprotein [P-gp]), resulting in an increased risk of myopathy and rhabdomyolysis.

Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir or glecaprevir plus pibrentasvir with CADUET is not recommended. CADUET dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2)]. Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (> 1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1)].

Consider if the benefit of use of these products outweighs the increased risk of myopathy and rhabdomyolysis [see Drug Interactions (7.3)]. Concomitant intake of large quantities, more than 1.2 liters daily, of grapefruit juice is not recommended in patients taking CADUET [see Drug Interactions (7.3)]. Discontinue CADUET if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected.

Muscle symptoms and CK elevations may resolve if CADUET is discontinued. Temporarily discontinue CADUET in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).

Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the CADUET dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

5.2 Immune-Mediated Necrotizing Myopathy

5.2 Immune-Mediated Necrotizing Myopathy There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG-CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents.

Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Discontinue CADUET if IMNM is suspected.

5.3 Hepatic Dysfunction

5.3 Hepatic Dysfunction Increases in serum transaminases have been reported with use of atorvastatin [see Adverse Reactions (6.1)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy.

Persistent increases to more than three times the ULN in serum transaminases have occurred in approximately 0.7% of patients receiving atorvastatin in clinical trials. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [see Use in Specific Populations (8.7)].

Consider liver enzyme testing before atorvastatin initiation and when clinically indicated thereafter. Atorvastatin is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue atorvastatin.

5.4 Increased Angina and Myocardial Infarction

5.4 Increased Angina and Myocardial Infarction Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of amlodipine, particularly in patients with severe obstructive coronary artery disease.

5.5 Hypotension

5.5 Hypotension Symptomatic hypotension is possible with use of amlodipine, particularly in patients with severe aortic stenosis. Because of the gradual onset of action, acute hypotension is unlikely.

5.6 Increases in HbA1c and Fasting Serum Glucose Levels

5.6 Increases in HbA1c and Fasting Serum Glucose Levels Increases in HbA1c and fasting serum glucose levels have been reported with statins, including atorvastatin. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.

5.7 Increased Risk of Hemorrhagic Stroke in Patients

5.7 Increased Risk of Hemorrhagic Stroke in Patients on Atorvastatin 80 mg with Recent Hemorrhagic Stroke In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial where 2365 adult patients, without CHD who had a stroke or Transient Ischemic Attack (TIA) within the preceding 6 months, were treated with atorvastatin 80 mg, a higher incidence of hemorrhagic stroke was seen in the atorvastatin 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively).

The incidence of non-fatal hemorrhagic stroke was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the atorvastatin group [see Adverse Reactions (6.1)].

Consider the risk/benefit of use of atorvastatin 80 mg in patients with recent hemorrhagic stroke.

Drug interactions

Drug interactions (US label) US FDA label

Data from a drug-drug interaction study involving 10 mg of amlodipine and 80 mg of atorvastatin in healthy subjects indicate that the pharmacokinetics of amlodipine are not altered when the drugs are co-administered. The effect of amlodipine on the pharmacokinetics of atorvastatin showed no effect on the C max: 91% (90% confidence interval: 80 to 103%), but the AUC of atorvastatin increased by 18% (90% confidence interval: 109 to 127%) in the presence of amlodipine, which is not clinically meaningful.

No drug interaction studies have been conducted with CADUET and other drugs, although studies have been conducted in the individual amlodipine and atorvastatin components, as described below:

  • See full prescribing information for details regarding concomitant use of CADUET with other drugs or grapefruit juice that increase the risk of myopathy and rhabdomyolysis (2.5, 7.3).
  • Rifampin: May reduce atorvastatin plasma concentrations. Administer simultaneously with atorvastatin (7.4).
  • Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive (7.5).
  • Digoxin: May increase digoxin plasma levels; monitor patients appropriately (7.5). Amlodipine
7.1 Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration

7.1 Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment [see Clinical Pharmacology (12.3)].

CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. Sildenafil Monitor for hypotension when sildenafil is co-administered with amlodipine [see Clinical Pharmacology (12.2)].

7.2 Impact of Amlodipine on Other Drugs Immunosuppressants

7.2 Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended and adjust the dose when appropriate [see Clinical Pharmacology (12.3)]. Atorvastatin

7.3 Drug

7.3 Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with Atorvastatin Atorvastatin is a substrate of CYP3A4 and transporters (e.g., OATP1B1/1B3, P-gp, or BCRP). Atorvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP3A4 and transporters. Table 3 includes a list of drugs that may increase exposure to atorvastatin and may increase the risk of myopathy and rhabdomyolysis when used concomitantly and instructions for preventing or managing them [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

Table 3. Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with Atorvastatin Cyclosporine or Gemfibrozil Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of atorvastatin and cyclosporine, an inhibitor of CYP3A4 and OATP1B1 [see Clinical Pharmacology (12.3)].

Gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine or gemfibrozil with atorvastatin. Intervention: Concomitant use of cyclosporine or gemfibrozil with atorvastatin is not recommended. Anti-Viral Medications Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of atorvastatin with many anti-viral medications, which are inhibitors of CYP3A4 and/or transporters (e.g., BCRP, OATP1B1/1B3, P-gp, MRP2, and/or OAT2) [see Clinical Pharmacology (12.3)].

Cases of myopathy and rhabdomyolysis have been reported with concomitant use of ledipasvir plus sofosbuvir with atorvastatin. Intervention:

  • Concomitant use of tipranavir plus ritonavir or glecaprevir plus pibrentasvir with atorvastatin is not recommended.
  • In patients taking lopinavir plus ritonavir, or simeprevir, consider the risk/benefit of concomitant use with atorvastatin.
  • In patients taking saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir or letermovir do not exceed atorvastatin 20 mg.
  • In patients taking nelfinavir, do not exceed atorvastatin 40 mg [see Dosage and Administration (2)].
  • Consider the risk/benefit of concomitant use of ledipasvir plus sofosbuvir with atorvastatin.
  • Monitor all patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Examples: Tipranavir plus ritonavir, glecaprevir plus pibrentasvir, lopinavir plus ritonavir, simeprevir, saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir, letermovir, nelfinavir, and ledipasvir plus sofosbuvir. Select Azole Antifungals or Macrolide Antibiotics Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of atorvastatin with select azole antifungals or macrolide antibiotics, due to inhibition of CYP3A4 and/or transporters [see Clinical Pharmacology (12.3)]. Intervention: In patients taking clarithromycin or itraconazole, do not exceed atorvastatin 20 mg [see Dosage and Administration (2)]. Consider the risk/benefit of concomitant use of other azole antifungals or macrolide antibiotics with atorvastatin. Monitor all patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Examples: Erythromycin, clarithromycin, itraconazole, ketoconazole, posaconazole, and voriconazole. Niacin Clinical Impact: Cases of myopathy and rhabdomyolysis have been observed with concomitant use of lipid modifying dosages of niacin (> 1 gram/day niacin) with atorvastatin. Intervention: Consider if the benefit of using lipid modifying dosages of niacin concomitantly with atorvastatin outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Fibrates (other than Gemfibrozil) Clinical Impact: Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with atorvastatin. Intervention: Consider if the benefit of using fibrates concomitantly with atorvastatin outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Colchicine Clinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with atorvastatin. Intervention: Consider the risk/benefit of concomitant use of colchicine with atorvastatin. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Grapefruit Juice Clinical Impact: Grapefruit juice consumption, especially excessive consumption, more than 1.2 liters/daily can raise the plasma levels of atorvastatin and may increase the risk of myopathy and rhabdomyolysis. Intervention: Avoid intake of large quantities of grapefruit juice, more than 1.2 liters daily, when taking atorvastatin.
7.4 Drug

7.4 Drug Interactions that may Decrease Exposure to Atorvastatin Table 4 presents drug interactions that may decrease exposure to atorvastatin and instructions for preventing or managing them. Table 4. Drug Interactions that may Decrease Exposure to Atorvastatin Rifampin Clinical Impact: Concomitant administration of atorvastatin with rifampin, an inducer of cytochrome P450 3A4 and inhibitor of OATP1B1, can lead to variable reductions in plasma concentrations of atorvastatin.

Due to the dual interaction mechanism of rifampin, delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. Intervention: Administer atorvastatin and rifampin simultaneously.

7.5 Atorvastatin Effects on Other Drugs

7.5 Atorvastatin Effects on Other Drugs Table 5 presents atorvastatin's effect on other drugs and instructions for preventing or managing them. Table 5. Atorvastatin Effects on Other Drugs Oral Contraceptives Clinical Impact: Co-administration of atorvastatin and an oral contraceptive increased plasma concentrations of norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)].

Intervention: Consider this when selecting an oral contraceptive for patients taking atorvastatin. Digoxin Clinical Impact: When multiple doses of atorvastatin and digoxin were co-administered, steady state plasma digoxin concentrations increased [see Clinical Pharmacology (12.3)]. Intervention: Monitor patients taking digoxin appropriately.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

CYP3A inhibitors : Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure.

However, strong inhibitors of CYP3A (e.g., itraconazole, clarithromycin) may increase the plasma concentrations of amlodipine to a greater extent [see Drug Interactions (7.1) ] .

Atorvastatin : Atorvastatin is a substrate of the hepatic transporters, OATP1B1 and OATP1B3 transporter.

Metabolites of atorvastatin are substrates of OATP1B1.

Atorvastatin is also identified as a substrate of the efflux transporter BCRP, which may limit the intestinal absorption and biliary clearance of atorvastatin.

Tacrolimus : A prospective study in healthy Chinese volunteers (N=9) with CYP3A5 expressers showed a 2.5- to 4-fold increase in tacrolimus exposure when concomitantly administered with amlodipine compared to tacrolimus alone.

This finding was not observed in CYP3A5 non-expressers (N=6).

However, a 3-fold increase in plasma exposure to tacrolimus in a renal transplant patient (CYP3A5 non-expresser) upon initiation of amlodipine for the treatment of post-transplant hypertension resulting in reduction of tacrolimus dose has been reported.

Adverse reactions

Adverse reactions (US label) US FDA label

The following important adverse reactions are described below and elsewhere in the labeling:

  • Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.1)]
  • Immune-Mediated Necrotizing Myopathy [see Warnings and Precautions (5.2)]
  • Hepatic Dysfunction [see Warnings and Precautions (5.3)]
  • Increases in HbA1c and Fasting Serum Glucose Levels [see Warnings and Precautions (5.6)] Most common adverse reaction to amlodipine is edema which occurred in a dose related manner (6.1). Most common adverse reactions (incidence ≥ 5%) are nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection to atorvastatin (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. CADUET CADUET (amlodipine/atorvastatin) has been evaluated for safety in 1092 patients in double-blind placebo-controlled studies treated for co-morbid hypertension and dyslipidemia.

In general, treatment with CADUET was well tolerated. For the most part, adverse reactions have been mild or moderate in severity. In clinical trials with CADUET, no adverse reactions peculiar to this combination have been observed. Adverse reactions are similar in terms of nature, severity, and frequency to those reported previously with amlodipine and atorvastatin.

The following information is based on the clinical experience with amlodipine and atorvastatin. Amlodipine Amlodipine has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. In general, treatment with amlodipine was well tolerated at doses up to 10 mg daily. Most adverse reactions reported during therapy with amlodipine were of mild or moderate severity.

In controlled clinical trials directly comparing amlodipine (N=1730) at doses up to 10 mg to placebo (N=1250), discontinuation of amlodipine because of adverse reactions was required in only about 1.5% of patients and was not significantly different from placebo (about 1%). The most commonly reported side effects more frequent than placebo are dizziness and edema.

The incidence (%) of side effects that occurred in a dose related manner are as follows: Amlodipine 2.5 mg 5 mg 10 mg Placebo N=275 N=296 N=268 N=520 Edema 1.8 3.0 10.8 0.6 Dizziness 1.1 3.4 3.4 1.5 Flushing 0.7 1.4 2.6 0.0 Palpitations 0.7 1.4 4.5 0.6 Other adverse reactions that were not clearly dose related but were reported at an incidence greater than 1.0% in placebo-controlled clinical trials include the following: Amlodipine (%) Placebo (%) (N=1730) (N=1250) Fatigue 4.5 2.8 Nausea 2.9 1.9 Abdominal Pain 1.6 0.3 Somnolence 1.4 0.6 Edema, flushing, palpitations, and somnolence appear to be more common in women than in men. The following events occurred in < 1% but > 0.1% of patients treated with amlodipine in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship: Cardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, peripheral ischemia, syncope, tachycardia, vasculitis.

Central and Peripheral Nervous System: hypoesthesia, neuropathy peripheral, paresthesia, tremor, vertigo. Gastrointestinal: anorexia, constipation, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia. General: allergic reaction, asthenia, back pain, hot flushes, malaise, pain, rigors, weight gain, weight decrease.

Musculoskeletal System: arthralgia, arthrosis, muscle cramps, myalgia. Psychiatric: sexual dysfunction (male and female), insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization. Respiratory System: dyspnea, epistaxis. Skin and Appendages: angioedema, erythema multiforme, pruritus, rash, rash erythematous, rash maculopapular.

Special Senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus. Urinary System: micturition frequency, micturition disorder, nocturia. Autonomic Nervous System: dry mouth, sweating increased. Metabolic and Nutritional: hyperglycemia, thirst. Hemopoietic: leukopenia, purpura, thrombocytopenia. These events occurred in less than 1% in placebo-controlled trials, but the incidence of these side effects was between 1% and 2% in all multiple dose studies.

These events occurred in less than 1% in placebo-controlled trials, but the incidence of these side effects was between 1% and 2% in all multiple dose studies. Amlodipine therapy has not been associated with clinically significant changes in routine laboratory tests. No clinically relevant changes were noted in serum potassium, serum glucose, total TG, TC, HDL-C, uric acid, blood urea nitrogen, or creatinine.

Atorvastatin In the atorvastatin placebo-controlled clinical trial database of 16066 patients (8755 atorvastatin vs. 7311 placebo; age range 10‑93 years, 39% female, 91% White, 3% Black or African American, 2% Asian, 4% other) with a median treatment duration of 53 weeks, the most common adverse reactions in patients treated with atorvastatin that led to treatment discontinuation and occurred at a rate greater than placebo were: myalgia (0.7%), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%). Table 2 summarizes adverse reactions, reported in ≥ 2% and at a rate greater than placebo in patients treated with atorvastatin (n=8755), from seventeen placebo-controlled trials.

Table 2. Adverse Reactions Occurring in ≥ 2% in Patients Atorvastatin-Treated with any Dose and Greater than Placebo Adverse Reaction % Placebo N=7311 % 10 mg N=3908 % 20 mg N=188 % 40 mg N=604 % 80 mg N=4055 % Any dose N=8755 Nasopharyngitis 8.2 12.9 5.3 7.0 4.2 8.3 Arthralgia 6.5 8.9 11.7 10.6 4.3

6.9 Diarrhea 6

6.9 Diarrhea 6.3 7.3 6.4 14.1 5.2

6.8 Pain

6.8 Pain in extremity 5.9 8.5 3.7 9.3 3.1

6.0 Urinary

6.0 Urinary tract infection 5.6 6.9 6.4 8.0 4.1 5.7 Dyspepsia 4.3 5.9 3.2 6.0 3.3 4.7 Nausea 3.5 3.7 3.7 7.1 3.8 4.0 Musculoskeletal pain 3.6 5.2 3.2 5.1 2.3 3.8 Muscle spasms 3.0 4.6 4.8 5.1 2.4 3.6 Myalgia 3.1 3.6 5.9 8.4 2.7 3.5 Insomnia 2.9 2.8 1.1 5.3 2.8 3.0 Pharyngolaryngeal pain 2.1 3.9 1.6 2.8 0.7 2.3 Other adverse reactions reported in placebo-controlled trials include: Body as a Whole: malaise, pyrexia Digestive System: abdominal discomfort, eructation, flatulence, hepatitis, cholestasis Musculoskeletal System: musculoskeletal pain, muscle fatigue, neck pain, joint swelling Metabolic and Nutritional System: transaminases increase, liver function test abnormal, blood alkaline phosphatase increase, creatine phosphokinase increase, hyperglycemia Nervous System: nightmare Respiratory System: epistaxis Skin and Appendages: urticaria Special Senses: vision blurred, tinnitus Urogenital System: white blood cells urine positive. Elevations in Liver Enzyme Tests Persistent elevations in serum transaminases, defined as more than 3 times the ULN and occurring on 2 or more occasions, occurred in 0.7% of patients who received atorvastatin in clinical trials.

The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively. One patient in clinical trials developed jaundice. Increases in liver enzyme tests in other patients were not associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae.

Eighteen of 30 patients with persistent liver enzyme elevations continued treatment with a reduced dose of atorvastatin. Treating to New Targets Study (TNT) In TNT, [see Clinical Studies (14.6)] 10,001 patients (age range 29–78 years, 19% female; 94% White, 3% Black or African American, 1% Asian, 2% other) with clinically evident CHD were treated with atorvastatin 10 mg daily (n=5006) or atorvastatin 80 mg daily (n=4995).

In the high-dose atorvastatin group, there were more patients with serious adverse reactions (1.8%) and discontinuations due to adverse reactions (9.9%) as compared to the low-dose group (1.4%; 8.1%, respectively) during a median follow-up of 4.9 years. Persistent transaminase elevations (≥ 3 x ULN twice within 4–10 days) occurred in 1.3% of individuals with atorvastatin 80 mg and in 0.2% of individuals with atorvastatin 10 mg.

Elevations of CK (≥ 10 x ULN) were higher in the high-dose atorvastatin group (0.3%) compared to the low-dose atorvastatin group (0.1%). Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) In SPARCL, 4731 patients (age range 21–92 years, 40% female; 93% White, 3% Black or African American, 1% Asian, 3% other) without clinically evident CHD but with a stroke or transient ischemic attack (TIA) within the previous 6 months were treated with atorvastatin 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years.

There was a higher incidence of persistent hepatic transaminase elevations (≥ 3 x ULN twice within 4–10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK (> 10 x ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). Diabetes was reported as an adverse reaction in 6.1% of subjects in the atorvastatin group and 3.8% of subjects in the placebo group.

In a post-hoc analysis, atorvastatin 80 mg reduced the incidence of ischemic stroke (9.2% vs. 11.6%) and increased the incidence of hemorrhagic stroke (2.3% vs. 1.4%) compared to placebo. The incidence of fatal hemorrhagic stroke was similar between groups (17 atorvastatin vs. 18 placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes).

Patients who entered the trial with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke (16% atorvastatin vs. 4% placebo). Adverse Reactions from Clinical Studies of Atorvastatin in Pediatric Patients with HeFH In a 26-week controlled study in pediatric patients with HeFH (ages 10 years to 17 years) (n=140, 31% female; 92% White, 1.6% Black or African American, 1.6% Asian, 4.8% other), the safety and tolerability profile of atorvastatin 10 to 20 mg daily, as an adjunct to diet to reduce total cholesterol, LDL-C, and apo B levels, was generally similar to that of placebo [see Use in Specific Populations (8.4) and Clinical Studies (14.11)].

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of amlodipine and atorvastatin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Amlodipine The following postmarketing event has been reported infrequently where a causal relationship is uncertain: gynecomastia. In postmarketing experience, jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis), in some cases severe enough to require hospitalization, have been reported in association with use of amlodipine.

Postmarketing reporting has also revealed a possible association between extrapyramidal disorder and amlodipine. Amlodipine has been used safely in patients with chronic obstructive pulmonary disease, well-compensated congestive heart failure, coronary artery disease, peripheral vascular disease, diabetes mellitus, and abnormal lipid profiles.

Atorvastatin Gastrointestinal Disorders: pancreatitis General Disorders: fatigue Hepatobiliary Disorders: fatal and non-fatal hepatic failure Immune System Disorders: anaphylaxis Injury: tendon rupture Musculoskeletal and Connective Tissue Disorders: rhabdomyolysis, myositis. There have been rare reports of immune-mediated necrotizing myopathy associated with statin use.

Nervous System Disorders: dizziness, peripheral neuropathy. There have been rare reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with the use of all statins. Cognitive impairment was generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).

There have been rare reports of new-onset or exacerbation of myasthenia gravis, including ocular myasthenia, and reports of recurrence when the same or a different statin was administered. Psychiatric Disorders: depression Respiratory Disorders: interstitial lung disease Skin and Subcutaneous Tissue Disorders: angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis)

Adverse reaction frequency tables (US label) US FDA label
Amlodipine
2.5 mg 5 mg 10 mg Placebo
N=275 N=296 N=268 N=520
Edema 1.8 3.0 10.8 0.6
Dizziness 1.1 3.4 3.4 1.5
Flushing 0.7 1.4 2.6 0.0
Palpitations 0.7 1.4 4.5 0.6
Amlodipine (%) Placebo (%)
(N=1730) (N=1250)
Fatigue 4.5 2.8
Nausea 2.9 1.9
Abdominal Pain 1.6 0.3
Somnolence 1.4 0.6
Adverse Reaction % Placebo N=7311 % 10 mg N=3908 % 20 mg N=188 % 40 mg N=604 % 80 mg N=4055 % Any dose N=8755
Nasopharyngitis 8.2 12.9 5.3 7.0 4.2 8.3
Arthralgia 6.5 8.9 11.7 10.6 4.3 6.9
Diarrhea 6.3 7.3 6.4 14.1 5.2 6.8
Pain in extremity 5.9 8.5 3.7 9.3 3.1 6.0
Urinary tract infection 5.6 6.9 6.4 8.0 4.1 5.7
Dyspepsia 4.3 5.9 3.2 6.0 3.3 4.7
Nausea 3.5 3.7 3.7 7.1 3.8 4.0
Musculoskeletal pain 3.6 5.2 3.2 5.1 2.3 3.8
Muscle spasms 3.0 4.6 4.8 5.1 2.4 3.6
Myalgia 3.1 3.6 5.9 8.4 2.7 3.5
Insomnia 2.9 2.8 1.1 5.3 2.8 3.0
Pharyngolaryngeal pain 2.1 3.9 1.6 2.8 0.7 2.3

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Atorvastatin Discontinue atorvastatin when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. Atorvastatin decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, atorvastatin may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology (12.1)].

In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations.

Published data from prospective and retrospective observational cohort studies with atorvastatin use in pregnant women are insufficient to determine if there is a drug-associated risk of miscarriage (see Data). In animal reproduction studies, no adverse developmental effects were observed in pregnant rats or rabbits orally administered atorvastatin at doses that resulted in up to 30 and 20 times, respectively, the human exposure at the maximum recommended human dose (MRHD) of 80 mg, based on body surface area (mg/m 2).

In rats administered atorvastatin during gestation and lactation, decreased postnatal growth and development delay were observed at doses ≥ 6 times the MRHD (see Data). Amlodipine The limited available data based on postmarketing reports with amlodipine use in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage.

There are risks to the mother and fetus associated with poorly controlled hypertension in pregnancy (see Clinical Considerations). In animal reproduction studies, there was no evidence of adverse developmental effects when pregnant rats and rabbits were treated orally with amlodipine maleate during organogenesis at doses approximately 10 and 20-times MRHD, respectively.

However for rats, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold). Amlodipine has been shown to prolong both the gestation period and the duration of labor in rats at this dose (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section and post-partum hemorrhage).

Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Data Human Data Atorvastatin A Medicaid cohort linkage study of 1152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders–including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods.

The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders.

In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births.

Animal Data Atorvastatin Was administered to pregnant rats and rabbits during organogenesis at oral doses up to 300 mg/kg/day and 100 mg/kg/day, respectively. Atorvastatin was not teratogenic in rats at doses up to 300 mg/kg/day or in rabbits at doses up to 100 mg/kg/day. These doses resulted in multiples of about 30 times (rat) or 20 times (rabbit) the human exposure at the MRHD based on surface area (mg/m 2).

In rats, the maternally toxic dose of 300 mg/kg resulted in increased post-implantation loss and decreased fetal body weight. At the maternally toxic doses of 50 and 100 mg/kg/day in rabbits, there was increased post-implantation loss, and at 100 mg/kg/day fetal body weights were decreased. In a study in pregnant rats administered 20, 100, or 225 mg/kg/day, from gestation day 7 through to lactation day 20 (weaning), there was decreased survival at birth, postnatal day 4, weaning, and post-weaning in pups of mothers dosed with 225 mg/kg/day, a dose at which maternal toxicity was observed.

Pup body weight was decreased through postnatal day 21 at 100 mg/kg/day, and through postnatal day 91 at 225 mg/kg/day. Pup development was delayed (rotorod performance at 100 mg/kg/day and acoustic startle at 225 mg/kg/day; pinnae detachment and eye-opening at 225 mg/kg/day). These doses of atorvastatin correspond to 6 times (100 mg/kg) and 22 times (225 mg/kg) the human exposure at the MRHD, based on AUC.

Atorvastatin crosses the rat placenta and reaches a level in fetal liver equivalent to that of maternal plasma. Amlodipine No evidence of teratogenicity or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses up to 10 mg amlodipine/kg/day (approximately 10 and 20 times the MRHD based on body surface area, respectively) during their respective periods of major organogenesis.

However, for rats, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold) in rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose.

Mechanism of action

12.1 Mechanism of Action CADUET is a combination of two drugs, a dihydropyridine calcium channel blocker (amlodipine) and an HMG-CoA reductase inhibitor (atorvastatin). The amlodipine component of CADUET inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The atorvastatin component of CADUET is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.

Amlodipine Amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells.

Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.

The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following: Exertional Angina: In patients with exertional angina, amlodipine reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise. Vasospastic Angina: Amlodipine has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro.

This inhibition of coronary spasm is responsible for the effectiveness of amlodipine in vasospastic (Prinzmetal's or variant) angina. Atorvastatin Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.

In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Amlodipine Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.

Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina. With chronic once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours.

Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with amlodipine is also correlated with the height of pretreatment elevation; thus, individuals with moderate hypertension (diastolic pressure 105–114 mmHg) had about a 50% greater response than patients with mild hypertension (diastolic pressure 90–104 mmHg).

Normotensive subjects experienced no clinically significant change in blood pressures (+1/–2 mmHg). In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or proteinuria.

As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with beta-blockers to man.

Similar findings, however, have been observed in normal or well-compensated patients with heart failure with agents possessing significant negative inotropic effects. Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing.

Similar results were obtained in patients receiving amlodipine and concomitant beta-blockers. In clinical studies in which amlodipine was administered in combination with beta-blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed. In clinical trials with angina patients alone, amlodipine therapy did not alter electrocardiographic intervals or produce higher degrees of AV blocks.

Atorvastatin Atorvastatin, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response [see Dosage and Administration (2)].

Drug Interactions Sildenafil: When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect [see Drug Interactions (7.1)].

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Excretion Amlodipine: Elimination from the plasma is biphasic with a terminal elimination half-life of about 30–50 hours.

Ten percent of the parent amlodipine compound and 60% of the metabolites of amlodipine are excreted in the urine.

Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours because of the contribution of active metabolites.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption Amlodipine: After oral administration of therapeutic doses of amlodipine alone, absorption produces peak plasma concentrations between 6 and 12 hours. Absolute bioavailability has been estimated to be between 64% and 90%. Atorvastatin: After oral administration alone, atorvastatin is rapidly absorbed; maximum plasma concentrations occur within 1 to 2 hours.

Extent of absorption increases in proportion to atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism.Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by C max and AUC,LDL-C reduction is similar whether atorvastatin is given with or without food Plasma atorvastatin concentrations are lower (approximately 30% for C max and AUC) following evening drug administration compared with morning.

However, LDL-C reduction is the same regardless of the time of day of drug administration. CADUET: Following oral administration of CADUET, peak plasma concentrations of amlodipine and atorvastatin are seen at 6 to 12 hours and 1 to 2 hours post dosing, respectively. The rate and extent of absorption (bioavailability) of amlodipine and atorvastatin from CADUET are not significantly different from the bioavailability of amlodipine and atorvastatin administered separately (see above).

The bioavailability of amlodipine from CADUET was not affected by food. Food decreases the rate and extent of absorption of atorvastatin from CADUET by approximately 32% and 11%, respectively, as it does with atorvastatin when given alone. LDL-C reduction is similar whether atorvastatin is given with or without food. Distribution Amlodipine: Ex vivo studies have shown that approximately 93% of the circulating amlodipine drug is bound to plasma proteins in hypertensive patients.

Steady-state plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily dosing. Atorvastatin: Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells.

Elimination Metabolism Amlodipine: Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism. Atorvastatin: Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin.

Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P4503A4, consistent with increased plasma concentrations of atorvastatin in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see Drug Interactions (7)].

In animals, the ortho-hydroxy metabolite undergoes further glucuronidation. Excretion Amlodipine: Elimination from the plasma is biphasic with a terminal elimination half-life of about 30–50 hours. Ten percent of the parent amlodipine compound and 60% of the metabolites of amlodipine are excreted in the urine. Atorvastatin: Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation.

Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours because of the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration. Specific Populations Geriatric Amlodipine: Elderly patients have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40–60%, and a lower initial dose of amlodipine may be required.

Atorvastatin: Plasma concentrations of atorvastatin are higher (approximately 40% for C max and 30% for AUC) in healthy elderly subjects (age ≥ 65 years) than in young adults. Pediatric Amlodipine: Sixty-two hypertensive patients aged 6 to 17 years received doses of amlodipine between 1.25 mg and 20 mg. Weight-adjusted clearance and volume of distribution were similar to values in adults.

Atorvastatin: Apparent oral clearance of atorvastatin in pediatric subjects appeared similar to that of adults when scaled allometrically by body weight as the body weight was the only significant covariate in atorvastatin population pharmacokinetics model with data including pediatric HeFH patients (ages 10 years to 17 years of age, n=29) in an open-label, 8-week study. Gender Atorvastatin: Plasma concentrations of atorvastatin in females differ from those in males (approximately 20% higher for C max and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with atorvastatin between males and females.

Renal Impairment Amlodipine: The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. Patients with renal failure may therefore receive the usual initial amlodipine dose. Atorvastatin: Renal disease has no influence on the plasma concentrations or LDL-C reduction of atorvastatin [see Use in Specific Populations (8.6)].

While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to clear atorvastatin or amlodipine since both drugs are extensively bound to plasma proteins. Hepatic Impairment Amlodipine: Elderly patients and patients with hepatic insufficiency have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40–60%.

Atorvastatin: In patients with chronic alcoholic liver disease, plasma concentrations of atorvastatin are markedly increased. C max and AUC are each 4-fold greater in patients with Childs-Pugh A disease. C max and AUC of atorvastatin are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see Use in Specific Populations (8.7)].

Heart Failure Amlodipine: In patients with moderate to severe heart failure, the increase in AUC for amlodipine was similar to that seen in the elderly and in patients with hepatic insufficiency. Effects of Other Drugs on CADUET Amlodipine: Co-administered cimetidine, magnesium-and aluminum hydroxide antacids, sildenafil, and grapefruit juice have no impact on the exposure to amlodipine.

CYP3A inhibitors: Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. Erythromycin co-administration in healthy volunteers did not significantly change amlodipine systemic exposure. However, strong inhibitors of CYP3A (e.g., itraconazole, clarithromycin) may increase the plasma concentrations of amlodipine to a greater extent [see Drug Interactions (7.1)].

Atorvastatin: Atorvastatin is a substrate of the hepatic transporters, OATP1B1 and OATP1B3 transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the efflux transporter BCRP, which may limit the intestinal absorption and biliary clearance of atorvastatin. Table 6 shows effects of other drugs on the pharmacokinetics of atorvastatin.

Table 6. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin Co-administered drug and dosage regimen Atorvastatin Dosage (mg) Ratio of AUC Represents ratio of treatments (co-administered drug plus atorvastatin vs atorvastatin alone). Ratio of C max See Sections 5.1 and 7 for clinical significance. Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD Once daily for 28 days 8.69 10.66 Tipranavir 500 mg BID Twice daily /ritonavir 200 mg BID, 7 days 10 mg SD Single dosage 9.36 8.58 Glecaprevir 400 mg QD /pibrentasvir 120 mg QD, 7 days 10 mg QD for 7 days 8.28 22.00 Telaprevir 750 mg q8h Every 8 hours, 10 days 20 mg SD 7.88 10.60, The dose of saquinavir plus ritonavir in this study is not the clinically used dose.

The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used. Saquinavir 400 mg BID /ritonavir 400 mg BID, 15 days 40 mg QD for 4 days 3.93 4.31 Elbasvir 50 mg QD /grazoprevir 200 mg QD, 13 days 10 mg SD 1.94 4.34 Simeprevir 150 mg QD, 10 days 40 mg SD 2.12 1.70 Clarithromycin 500 mg BID, 9 days 80 mg QD for 8 days 4.54 5.38 Darunavir 300 mg BID /ritonavir 100 mg BID, 9 days 10 mg QD for 4 days 3.45 2.25 Itraconazole 200 mg QD, 4 days 40 mg SD 3.32 1.20 Letermovir 480 mg QD, 10 days 20 mg SD 3.29 2.17 Fosamprenavir 700 mg BID /ritonavir 100 mg BID, 14 days 10 mg QD for 4 days 2.53 2.84 Fosamprenavir 1400 mg BID, 14 days 10 mg QD for 4 days 2.30 4.04 Nelfinavir 1250 mg BID, 14 days 10 mg QD for 28 days 1.74 2.22 Grapefruit Juice, 240 mL QD, Greater increases in AUC (ratio of AUC up to 2.5) and/or C max (ratio of C max up to 1.71) have been reported with excessive grapefruit consumption (≥ 750 mL – 1.2 liters per day). 40 mg SD 1.37 1.16 Diltiazem 240 mg QD, 28 days 40 mg SD 1.51 1.00 Erythromycin 500 mg QID Four times daily, 7 days 10 mg SD 1.33 1.38 Amlodipine 10 mg, single dose 80 mg SD 1.18 0.91 Cimetidine 300 mg QID, 2 weeks 10 mg QD for 2 weeks 1.00 0.89 Colestipol 10 g BID, 24 weeks 40 mg QD for 8 weeks NA 0.74 Ratio based on a single sample taken 8–16 h post dose.

Maalox TC ® 30 mL QID, 17 days 10 mg QD for 15 days 0.66 0.67 Efavirenz 600 mg QD, 14 days 10 mg for 3 days 0.59 1.01 Rifampin 600 mg QD, 7 days (co-administered) Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. 40 mg SD 1.12 2.90 Rifampin 600 mg QD, 5 days (doses separated) 40 mg SD 0.20 0.60 Gemfibrozil 600 mg BID, 7 days 40 mg SD 1.35 1.00 Fenofibrate 160 mg QD, 7 days 40 mg SD 1.03 1.02 Boceprevir 800 mg TID Three times daily, 7 days 40 mg SD 2.32 2.66 Effects of CADUET on Other Drugs Amlodipine: Amlodipine is a weak inhibitor of CYP3A and may increase exposure to CYP3A substrates. In vitro data indicate that amlodipine has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin.

Co-administered amlodipine does not affect the exposure to atorvastatin, digoxin, ethanol and the warfarin prothrombin response time. Cyclosporine: A prospective study in renal transplant patients (N=11) showed on an average of 40% increase in trough cyclosporine levels when concomitantly treated with amlodipine [see Drug Interactions (7.2)].

Tacrolimus: A prospective study in healthy Chinese volunteers (N=9) with CYP3A5 expressers showed a 2.5- to 4-fold increase in tacrolimus exposure when concomitantly administered with amlodipine compared to tacrolimus alone. This finding was not observed in CYP3A5 non-expressers (N=6). However, a 3-fold increase in plasma exposure to tacrolimus in a renal transplant patient (CYP3A5 non-expresser) upon initiation of amlodipine for the treatment of post-transplant hypertension resulting in reduction of tacrolimus dose has been reported.

Irrespective of the CYP3A5 genotype status, the possibility of an interaction cannot be excluded with these drugs [see Drug Interactions (7.2)]. Atorvastatin: Table 7 shows the effects of atorvastatin on the pharmacokinetics of other drugs. Table 7. Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs Atorvastatin Co-administered drug and dosage regimen Drug/Dosage (mg) Ratio of AUC Ratio of C max 80 mg QD Once daily for 15 days Antipyrine, 600 mg SD Single dosage 1.03 0.89 80 mg QD for 10 days See Section 7 for clinical significance.

Digoxin 0.25 mg QD, 20 days 1.15 1.20 40 mg QD for 22 days Oral contraceptive QD, 2 months – norethindrone 1 mg – ethinyl estradiol 35 µg 1.28 1.19 1.23 1.30 10 mg SD Tipranavir 500 mg BID Twice daily /ritonavir 200 mg BID, 7 days 1.08 0.96 10 mg QD for 4 days Fosamprenavir 1400 mg BID, 14 days 0.73 0.82 10 mg QD for 4 days Fosamprenavir 700 mg BID /ritonavir 100 mg BID, 14 days 0.99 0.94 Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Caduet · Viatris Specialty LLC [US FDA-approved label, version 3, September 30, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=164394b3-d7ba-4bbf-b64b-e2dd15735ea8
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .